... targeted therapy everolimus (RAD001) significantly delays cancer progression in patients with metastatic kidney ... 54,390 new cases of kidney cancer diagnosed in the US in 2008, and that about 13,010 ...
Scientists have identified a cleaved form of galectin-3 as a marker for prostate cancer progression.
... in green tea demonstrated a significant reduction in serum markers predictive of prostate cancer progression. "The investigational agent used in the trial, Polyphenon E (provided by Polyphenon Pharma) ...
... developmental processes involving biological cells. New findings indicate that alcohol may promote cancer progression by stimulating EMT.This has implications for both cancer prevention and therapy.
... -protein interaction has led researchers to an important genetic marker that can help physicians know which breast cancer patients are at highest risk and will require more aggressive treatment.
OKLAHOMA CITY, May 14 (UPI) -- U.S. medical scientists say they have discovered a compound that, in laboratory tests, has shown success in preventing cancer.
... genetic profiles, or signatures, to predict the likelihood that cancer would recur in patients whose non- ... basis for why some early stage lung cancers progress and metastasize and why some do not. He ...
... each only for a while. Last year his cancer count, or prostate specific antigen (PSA ... altered cells of the body, such as cancer cells. Whether a cancer progresses or not depends, in part, on the ability ...
... to identify a large number of markers which can be taken forward for further testing and then clinical trials, leading to their potential use in both diagnosis and monitoring of cancer progression."
... targeted and silenced TG2 in animal models, cancer progression was reversed, suggesting the protein may also provide a ... cell lines to animal models."
The American Cancer Society estimates 15,000 U.S ...
... makes carrots orange, has been found to increase lung cancer progression in a large clinical trial. Additionally ... my years of working on retinoids and breast cancer, I am a believer," he says. "And what ...
... lived a median of 10.7 months compared with 7.9 months for those who received a placebo. Time to cancer progression was also significantly longer in the treatment group: 5.5 vs. 2.8 months. Due to ...
... might need to hit ErbB2-expressing cancers with drugs against both ErbB2 and Brk," ... ways of putting their discovery of the role of Brk in cancer progression to good use. "We also think that Brk would ...
... "We do not believe that height itself matters in determining risk of prostate cancer or prostate cancer progression, but we speculate that factors that influence height may also influence cancer and ...
... of Dr. Dwinell, who had filed an earlier patent application on the use of CXCL12 in limiting cancer progression. This pending patent also involved a graduate student, Michael Wendt.
"While we were ...
